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Project background 
  
Alzheimer’s disease (AD) is the most common cause of dementia, accounting for approximately 60~70% 
of dementia cases. AD afflicts more than 35.6 million individuals worldwide and is expected to increase 
to 65.7 million by 2030 and 115.4 million by 2050 1; AD is a serious public health problem that is causing 
increased health care costs worldwide. Typically, AD is a relentlessly progressive disorder that initially 
manifests as severe loss of memory, particularly episodic memory.2 The disorder is not curable at present, 
and the mechanisms driving development of AD are not fully understood. Therefore, there is an urgent 
need to develop and characterize relevant AD transgenic animal models to facilitate translational research 
and preclinical testing of therapeutic agents.3 Furthermore, it is imperative to discover the underlying 
mechanisms that exacerbate AD, which hinder mitigation efforts to reduce the health burden of this disease. 
Studies have shown that epigenetic regulation (DNA methylation and miRNAs etc.), or heritable 
changes in gene expression that occur without directly altering the DNA sequence, offers a plausible 
mechanistic explanation, in addition to gene-environment interactions, for some of the molecular events 
linking disease onset and development.4-6 While the role of epigenetic alterations in brain plasticity and 
disease has been discussed,7-9 very few studies have examined the relation between epigenetic changes 
(miRNAs) and AD in a large animal-transgenic model. The goal of my laboratory, with expertise in 
epigenetic studies, is to define epigenetic mechanisms by which genetic and/or environmental exposures 
impact chronic diseases to improve overall health and treatment. Therefore, I proposed to define epigenetic 
alterations associated with AD development by profiling expression of miRNAs using an AD transgenic 
pig with a multi-cistronic vector system generated by Dr. Se-Pill Park at Jeju National University Stem 
Cell Research Center (JNUSCRC), South Korea.  
 
Project progress  
 
With the generous support of GRIP, I could visit JNUSRC in Korea to collaborate on research and initiate 
the experimental phase of this project. I visited Dr. Park’s laboratory at JNUSRC in July 2017 and 
discussed the generation of several AD transgenic pig models with multi-cistronic vector systems as well 
as the best experimental design for measuring epigenetic alterations in AD. Consequently, I received brain 
tissues from two different aged AD transgenic pigs (7-week and 3-months old) and one control pig from 
Dr. Park at JNUSCRC in April 2018;  I just completed profiling the expression of 134 miRNAs using the 
nCounter Analysis System. Currently, I am working on statistical analyses to identify specific miRNAs 
relevant to AD development, and I will further determine miRNA-mRNA target recognition and 
functional networks using the Ingenuity Pathway Analysis (IPA) tool this fall.  
 
Impact of project and future direction 
 
• UM’s internalization and collaboration: This study will be completed through an international 
collaboration with Dr. Se-Pill Park at JNUSCRC, Korea, a well-known Korean scholar in stem cell 
research. As such, it will significantly advance the internationalization of UM. In addition, I plan 
further research collaborations with Dr. Sarjubhai Patel at the Department of Biomedical and 
Pharmaceutical Sciences, UM using AD transgenic pigs from Korea; this in turn, will result in multiple 
collaborations within UM as well as Jeju National University in Korea that will be beneficial for both 
universities.  
 
• Student research and mentorship: Through this GRIP support, I will expand my current epigenetic 
knowledge base and develop new research areas (i.e. AD). Furthermore, I instructed and supervised 
one graduate (Beth Cole) and two undergraduate students (Caroline Maughan and Minsun Koo) when 
performing the epigenetic analyses using the samples from Korea. The students will also be trained to 
work with IPA software to determine miRNA-mRNA relationships and their functional networks and 
pathways in AD development. 
 
• Manuscript in preparation: I am working on a manuscript titled “miRNAs expression in Alzheimer’s 
disease: using transgenic pigs with multi-cistronic vector system”, and I will submit this to a high 
impact peer-reviewed journal (i.e. Clinical Epigenetics) this winter. 
  
• External Funding proposal under development:  I am currently generating preliminary data for grant 
applications, and this, combined with the expansion of my expertise, will improve my chances of 
acquiring outside funding. I plan to apply for external funding (i.e. Alzheimer’s Association or NIH) 
by February 2020.  
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